Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Millennium Health
Shilpa Medicare’s Plan For Eylea Biosimilar Spells Ambition, But Path Not Easy
Shilpa Medicare’s plan for trials of an Eylea biosimilar shows the company’s ambition to leapfrog to a biosimilars-led growth strategy, one that Indian majors like Cipla and Lupin pivoted to post a successful generics program. However, the path isn’t going to be easy and Biocon/Viatris, Samsung Biologics are ahead
- Digital Health
- Pharmacy Services, PBMs
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.